General
Preferred name
Miridesap
Synonyms
CPHPC ()
Ro63-8695 ()
GSK2315698 ()
GSK-2315698 ()
RO-638695 ()
RO 63-8695 ()
P&D ID
PD017365
CAS
224624-80-0
Tags
available
drug candidate
Drug indication
Parkinson disease
Drug Status
investigational
Max Phase
Phase 2
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Miridesap (CPHPC) is reported as a chemical which depletes the glycoprotein serum amyloid P component (SAP) in mice and humans . Intellectual property for the use of CPHPC has been licensed to GlaxoSmithKline who have coded the compound GSK2315698. Structurally, CPHPC is a simplified form of a dimer . Mechanistically miridesap cross-links pairs of SAP molecules in serum forming complexes that are rapidly cleared from the body and disrupts SAP binding to amyloid fibrils and neurofibrillary tangles . SAP is a drug target for the treament of neurodegenerative diseases (amyloidoses) . (GtoPdb)
Compound Sets
10
Cayman Chemical Bioactives
75500
ChEMBL Drugs
CHEMBL25263
Drug Repurposing Hub
DrugBank
DB13087
DrugMAP
DM1ZGUX
Guide to Pharmacology
8256
MedChem Express Bioactive Compound Library
HY-101861
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
T7295
External IDs
26
Properties
(calculated by RDKit )
Molecular Weight
340.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
0
cLogP
0.7
TPSA
115.22
Fraction CSP3
0.75
Chiral centers
2.0
Largest ring
5.0
QED
0.66
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Member status
member
MOA
Antiamyloidogenic Agents
Anti-Human Serum Amyloid P (Anti-SAP)
amyloid protein inhibitor
Source data